This Week in GLP-1s / April 19-25, 2026
FDA updates liraglutide label, removing pregnancy contraindication and suicide warning
Lead item
FDA updates liraglutide label, removing pregnancy contraindication and suicide warning
The FDA has made several changes to the official prescribing label for liraglutide, the GLP-1 medication sold for weight management, with updates dated between May 2025 and early 2026. According to the updated label posted on DailyMed, the agency removed a previous contraindication against use during pregnancy, eliminated a warning about suicidal behavior and ideation, and added a new warning about severe gastrointestinal side effects. A section on patient selection guidance was also removed from the dosing instructions.
Label updates like these reflect the FDA's ongoing review of real-world safety data and clinical evidence as it accumulates after a drug reaches the market. The removal of the pregnancy contraindication does not mean the drug has been declared safe in pregnancy — it means the FDA determined that the previous blanket restriction needed to be reworded or reclassified based on updated evidence; patients who are pregnant or planning pregnancy should discuss their specific situation with their prescriber. The removal of the suicide and self-harm warning follows a broader FDA review of GLP-1 medications and that risk category, while the new gastrointestinal warning signals that the agency wants prescribers to pay closer attention to serious digestive side effects. The existing boxed warning, the FDA's most serious caution, about a potential risk of a rare thyroid cancer called medullary thyroid carcinoma remains in place, though the agency notes this risk has been observed in animal studies and its relevance to humans is still not established.
Readers currently taking liraglutide or considering it should know that label changes do not require any immediate action on their part, but they are worth discussing at the next appointment with a doctor or pharmacist. The full updated prescribing information is publicly available through the FDA's DailyMed database for anyone who wants to review the specific language changes.
New Science on GLP-1 Mechanisms & Targets
Semaglutide shows liver benefits in mouse study
A study in mice with fatty liver disease found that semaglutide acts on specific liver cells to reduce inflammation, as reported by Reuters and published in Cell Metabolism. The drug shifted gene activity in liver sinusoidal endothelial cells, prompting them to release anti-inflammatory molecules. Because these findings come from a mouse study, it is not yet clear whether the same mechanism occurs in humans.
What this means for patients
This mouse study helps explain how drugs like Ozempic and Wegovy might reduce liver inflammation, but results in animals don't always carry over to people, so more research is needed before drawing conclusions for patients.
Some researchers question GLP-1 targeting for weight loss
STAT News reports that researchers involved in developing GLP-1 obesity drugs are exploring whether targeting the GLP-1 hormone is actually necessary to achieve weight loss. This represents a provocative shift in thinking within the field, though the article does not present new clinical trial data. The hypothesis remains preliminary and has not yet been tested in human studies.
Off-Label Demand & Social Media Health Trends
Everyone wants this unapproved weight loss drug
An unapproved weight loss drug called retatrutide is generating intense interest online, with some people finding ways to obtain it despite it still being in Phase 3 clinical trials. SELF Magazine reports that the FDA has stressed it is illegal to sell the drug, and experts caution against using any medication that has not completed testing and received approval.
These foods are being called 'natural GLP-1s'
Social media influencers are promoting certain foods like yerba mate and cinnamon as natural alternatives that mimic the effects of GLP-1 weight loss drugs. HuffPost reports that while balanced meals with protein, fiber, and healthy fats can help stabilize blood sugar and reduce cravings, experts emphasize that no food can truly replicate how these medications reduce persistent thoughts about eating.